Global hypoxia shortened atrial and ventricular APD. Glibenclamide but not CPT reversed this effect of hypoxia on ventricular but not atrial MAP. CPT but not glibenclamide reversed the effect of hypoxia on atrial MAP. In addition, CPT delayed the appearance of the atrioventricular (AV) nodal conduction block associated with global hypoxia. Finally, the ability of CPT to selectively attenuate A,-adenosine receptormediated effects of adenosine agonists in ventricular and supraventricular tissues was confirmed in 17 animals. CPT reversed the negative dromotropic effect of adenosine on AV nodal conduction and the antiadrenergic effect of N6-cyclopentyladenosine (CPA) mediated by A1-adenosine receptor but not the adenosine-induced decrease in systemic blood pressure caused by the vasodilatory action of the nucleoside mediated by A2-adenosine receptor.
Conclusions ( Key Words * adenosine * potassium * hypoxiaaction potentials * receptors T he purine nucleoside adenosine is released into the extracellular spaces during physiological and pathophysiological conditions associated with altered oxygen supply/demand ratio.' Once outside of cells, adenosine exerts pronounced effects on the mammalian heart, including a negative chronotropic effect on cardiac pacemakers, a negative dromotropic effect on atrioventricular (AV) nodal conduction, a negative inotropic effect on atrial myocardium, a vasodilatory effect on the coronary arteries, an antiadrenergic effect, an inhibitory effect on neutrophil activation, an anti-platelet aggregation effect, and a modulatory effect on cardiac metabolism. Taken together, these effects characterize adenosine as an endogenous cardioprotective agent. 2 Recently, it has been shown that adenosine can activate ATP-sensitive potassium (K+ATP) channels and that this action is mediated by A,-adenosine receptors (A,-AdoR).34 In addition, the activation of K+ATP channels by adenosine was suggested to play a mechanistic role in the vasodilatory effect of adenosine in porcine coronary arteries. 5 Since the activation of K+ATP channels has been proposed to exert a protective effect in the ischemic/hypoxic myocardium,6-1" it is tempting to speculate that activation of these channels by adenosine is another manifestation of its cardioprotective effects. Thus, the present experiments were aimed at testing the hypothesis that endogenous adenosine activates K+ATP channels during acute global myocardial hypoxia in vivo. For this purpose, a guinea pig model was used in which the release of endogenous adenosine and activation of A1-AdoR during global myocardial hypoxia have been well documented.12"13
Methods

Animal Preparation and Instrumentation
Guinea pigs (n=62) anesthetized with 98% ketamine plus 2% acepromazine 1.65 mL/kg IV and intubated with an endotracheal tube were ventilated with room air supplemented as necessary with oxygen using a Harvard respirator (model 665). The heart was exposed via To eliminate potential complications from the antiadrenergic action of adenosine and to determine the temporal pattern of APD, group 4 animals (n=7) were subjected to global hypoxia as described above after administration of propranolol (1 mg/kg IV). In group 5 (n=7), CPT (0.3 mg/kg IV) was also administered before hypoxia. In both groups (ie, 4 and 5), RV pacing was operative (paced cycle length, 240 milliseconds) throughout experimentation.
Characterization of CPT Actions
To verify that CPT is a selective A,-AdoR antagonist in ventricular and supraventricular tissues of the guinea pig heart in vivo, the following experiments were performed. First, the effects of CPT on the negative dromotropic and vasodilatory actions of adenosine mediated by A,-AdoR and A2-AdoR, respectively, were determined. In group 6 (n=6), exogenous adenosine (0.5, 1.0, and 1.5 ,umol/kg) was given during right atrial pacing in the absence and presence of CPT (0.3 mg/kg IV), and AV nodal conduction was quantified. In five other animals (group 7), the vasodilatory action of adenosine (1.5 ,umol/kg) on peripheral resistive blood vessels quantified as systemic arterial blood pressure was determined during sequential AV pacing (to exclude interference by AV conduction delays caused by adenosine) in the absence (control) and presence of CPT (0.3 mg/kg IV).
Finally, to determine the effect of CPT on ventricular A,-AdoR, the antiadrenergic action of A1-AdoR agonist N6-cyclopentyladenosine (CPA, 2 g.tmol/kg IV) was determined in group 8 (n=6) as follows: The positive inotropic action of isoproterenol (0.1 ,ug/kg IV) quantified as left ventricular dP/dt was determined during AV sequential pacing in the absence (control) and presence of CPA followed by CPT (0.3 mg/kg IV).
MAP Recordings
Custom-made electrodes were used for MAP recordings. For epicardial recording, a mini suction electrode was constructed from polyethylene tubing 2 mm in diameter and two isolated silver wires (Ag, 5T, Medwire Co, New York, NY), the tip of which was chlorinated to create a Ag/AgCl junction. Then silver wires were inserted into the polyethylene tubing and glued in place such that their tips were 0.5 mm proximal to the tip of the tubing and 1 mm away from each other. Negative pressure was applied to the polyethylene tubing using a 3-mL syringe fitted with a stopcock.
For intramyocardial MAP recording, one silver wire, the same as described above, was plunged by use of a needle (23 gauge), and the other wire was positioned epicardially next to the plunge site by use of saline-soaked cotton.
MAP electrodes were connected to a high-impedance am- (Tables 2 and 3 ). This was associated with a mild decrease in systemic arterial blood pressure and the appearance of AV nodal conduction block (Tables 2  and 3 ). Glibenclamide reversed the effect of hypoxia on APD but not on AV nodal conduction. In contrast, CPT delayed the appearance of a complete AV nodal conduction block but did not affect the shortening of ventricular APD (Tables 2 and 3 ).
Effects of Hypoxia on Atrial APD
Global myocardial hypoxia significantly shortened atrial APD compared with normoxic conditions (Table 
Characterization of CPT Action
As can be seen in Table 5 , CPT acted as a selective A,-AdoR antagonist in this guinea pig model. Specifically, CPT markedly attenuated the negative dromotropic action of exogenous adenosine (mediated by A1-AdoR) on AV nodal conduction expressed as prolongation of adenosine of PR and atrio-His intervals and the number of adenosine-induced nonconducted atrial beats (Table 5 , A). In contrast, CPT did not significantly affect the reduction of systemic arterial blood pressure caused by the vasodilatory action of adenosine (mediated by A2-AdoR) on peripheral resistive vessels (Table 5 , B). Data in Table 5 , C indicate that CPT effectively antagonizes the antiadrenergic action of the adenosine derivative CPA mediated by ventricular A,-AdoR. Indeed, CPA markedly attenuated the positive inotropic action of isoproterenol expressed as left ventricular dP/dt, and CPT reversed this action of CPA (Table 5 , C).
Discussion Present Findings
The major findings of the present study were that (1) CPT, a selective A1-AdoR antagonist, did not alter the effects of global cardiac hypoxia on ventricular myocardial MAP, nor did it alter their temporal pattern; (2) in contrast, CPT prevented the shortening of the atrial myocardial MAP duration caused by hypoxia; (3) CPT also antagonized hypoxia-induced AV nodal conduction delay; (4) glibenclamide markedly attenuated the pina- 
CPT as a Pharmacological Tool
In the present study, CPT was used as a selective A1-AdoR antagonist in the ventricular and supraventricular tissues of the guinea pig heart in vivo. Data of Table  5 confirm previous studies14 that indicated that CPT is a selective A,-AdoR antagonist. Indeed, CPT antagonized the negative dromotropic action of adenosine on AV nodal conduction and the antiadrenergic action of CPA, both of which are known to be mediated by A1-AdoR without significantly altering the vasodilatory action of adenosine, which is known to be mediated by A,-AdoR.
Relation to Previous Studies
Numerous in vitro and in vivo studies using cellular electrophysiological techniques have documented the pronounced alterations in cell membrane action potential caused by acute hypoxia/ischemia. These include cell membrane depolarization leading to reduced am- ing negative chronotropic and dromotropic actions on sinus node automaticity and AV nodal conduction, respectively, as well as shortening of atrial myocardial refractoriness; and (3) these actions are mediated by A1-AdoR and pertussis toxin-sensitive G protein.
It can be concluded that CPT prevented the shortening of atrial APD by blocking A1-AdoR in this tissue. This conclusion is supported by the finding that in the present experimental model, CPT antagonized the detrimental effect of hypoxia on AV nodal conduction. This latter observation indicates that substantial amounts of endogenous adenosine were released into the extracellular fluid, which altered AV nodal conduction. Similar conclusions were obtained in a previous study using a different selective A1-AdoR antagonist.13 Moreover, since CPT did not alter the effects of hypoxia on ventricular APD, it can be concluded that activation of K+ATP channels by adenosine does not play a major role in the mechanism of hypoxia-induced shortening of ventricular APD. This accords with the fact that no significant IK+,Ado,Ach is found in guinea pig ventricular myocytes.4
Furthermore, since CPT did not alter the temporal pattern of APD shortening, this argues against an early effect of adenosine on K+ATP channels that is masked by subsequent activation of these channels via change in intracellular ATP levels.
Adenosine and Cardioprotection
Adenosine has been shown to act as an endogenous cardioprotective agent2 and a mediator of ischemic/hypoxic preconditioning.18 Since adenosine was suggested to activate K+ATP channels,34 the activation of which is believed to play a mechanistic role in preconditioning, it has been assumed that K+ATP channels mediate, at least in part, the cardioprotective effects of adenosine. In the present study, glibenclamide did not alter the electrophysiological effects of endogenous adenosine. These data could explain the inability of glibenclamide to prevent preconditioning in rabbit19 and rat hearts. 20 The lack of effect of glibenclamide on preconditioning is in accord with the present conclusion that endogenous adenosine 
